Lecture: 25th Enders Lecture, featuring Napoleone Ferrara- 10/03/2018.

The Research Faculty Council Education Committee invites you to the 25th Annual John F. Enders Lecture, honoring Napoleone Ferrara, MD. Ferrara earned his MD in 1981 from the University of Catania Medical School in Italy. After completing his postdoctoral research at the University of California, San Francisco, he joined Genentech Inc. in 1988. There, he spent nearly 25 years working on the isolation, molecular cloning and biological characterization of VEGF-A, which resulted in the development of bevacizumab, the first anti-angiogenic agent to be approved by the FDA for cancer therapy. His research also led to the development of ranibizumab, which has been FDA-approved for the treatment of multiple intraocular neovascular disorders. In December 2012, Ferrara joined the University of California, San Diego as a distinguished professor of pathology, distinguished adjunct professor of ophthalmology & pharmacology, and senior deputy director for basic science of the Moores Cancer Center. His research currently focuses on investigating mechanisms of tumor angiogenesis alternative to VEGF, in particular, the role of factors produced by myeloid cells and fibroblasts.